Results 141 to 150 of about 10,858 (213)

Five-Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment. [PDF]

J Gastroenterol Hepatol
Ogawa E, Kohjima M, Koyanagi T, Dohmen K, Ooho A, Kawano A, Furusyo N, Kajiwara E, Satoh T, Takahashi K, Azuma K, Sugimoto R, Ichiki Y, Senju T, Amagase H, Tanaka M, Nakamuta M, Nomura H, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.   +19 more
europepmc   +1 more source

Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real-world evidence from the OPERA cohort. [PDF]

HIV Med
Pierone G, Brunet L, Fusco JS, Sension MG, Dunbar MS, Gruber J, Dieterich DT, Fusco GP.   +7 more
europepmc   +1 more source

Long-Term Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B: Raising the Need for Studies on Functional Cure-Editorial on "Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B". [PDF]

Korean J Gastroenterol
Lee SK.
europepmc   +1 more source

Optimized strategy of switching to tenofovir alafenamide fumarate treatment for nucleos(t)ide analogue experienced patients with chronic hepatitis B. [PDF]

Front Med (Lausanne)
Hu X, Kong Y, Liu Y, Liu T, Ma A, Li Y, Zhang Y, Li J, Zhang L, Li G.   +9 more
europepmc   +1 more source

Cellular pharmacology of tenofovir alafenamide and emtricitabine in neutrophils and platelets in people with and without HIV. [PDF]

J Antimicrob Chemother
Mainella VA, Branchford B, Nemkov T, Hosford S, Coyle RP, Johnson B, Choi YJ, Williams M, Zheng JH, Bushman L, Kiser JJ, Anderson PL, Brooks KM.   +12 more
europepmc   +1 more source

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study). [PDF]

Clin Infect Dis
Serrano-Villar S, Martín-Pedraza L, Tiraboschi J, Novella M, Cabello-Úbeda A, López-Cortés L, Busca C, Torralba M, Crusells MJ, Hidalgo-Tenorio C, Estrada V, Del Amo-de Palacios A, Díaz de Santiago A, Fons-Contreras M, Santos J, Bernal E, Montero-Alonso M, Troya J, Blanco JR, Burgos J, de Miguel M, Moreno S.   +21 more
europepmc   +1 more source

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV in Korea: 24-Month Data from BICSTaR. [PDF]

Infect Chemother
Kim YS, Choi JY, Park DW, Kim SW, Kim TH, Ryu J, Harrison R, Lee JA, Park F, Lee SH.   +9 more
europepmc   +1 more source

BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV-Infected Patients. [PDF]

AIDS Res Treat
Pérez-Calvo F, Jover-Diaz F, Delgado-Sánchez E, Peris-García J, Bernabéu-Martínez MÁ.   +4 more
europepmc   +1 more source

Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices During Pregnancy and Postpartum. [PDF]

Clin Pharmacokinet
Yu Y, Brooks KM, Doncel GF, Best BM, Marzinke MA, Mirochnick M, Anderson P, Myer L, Celum C, Heffron R, Coleman J, Davey DJ, Hendrix CW, Momper JD, Bies R, Scott RK.   +15 more
europepmc   +1 more source

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People Living with HIV Aged 50 Years and Older: A Retrospective Analysis of Naïve and Treatment-Experienced Individuals. [PDF]

Viruses
Trizzino M, Pipitò L, Di Figlia F, Bonura S, Zimmerhofer F, Cicero A, Gioè C, Cascio A.   +7 more
europepmc   +1 more source